With several choices for oral anticoagulation in Nonvalvular Atrial Fibrillation (NVAF), it is critical for pharmacists to be able to account for patient specific factors when selecting the most appropriate anticoagulant.
To learn more, visit www.ashpadvantage.com/nvaf
SPEAKERS
James S. Kalus, PharmD, FASHP, is Director of Pharmacy at Henry Ford Health System in Detroit, Michigan where he is responsible for planning, implementing, and managing all pharmacy services related to patient care including staff training and development, and pharmacy research. Dr. Kalus also serves as Program Director for the postgraduate year one (PGY1) residency at Henry Ford Hospital and is adjunct assistant professor of pharmacy and medicine at Wayne State University. In his research, Dr. Kalus has focused on cardiovascular disease, including the pathophysiology of atrial fibrillation (AF) occurring after cardiac surgery, novel strategies for the treatment and prevention of AF, practice-based research related to anticoagulation and implementation science related to clinical pharmacy services.
Devin Lavender, PharmD, BCPS, BCACP is Clinical Assistant Professor at the University of Georgia College of Pharmacy in Athens, Georgia where he practices in Ambulatory Care and chronic disease management at the Athens Community Based Outpatient Clinic affiliated with the Charlie Norwood VA Medical Center. Dr. Lavender obtained his PharmD degree from The University of Georgia College of Pharmacy. He completed a PGY1 Pharmacy Practice Residency at the Memphis VA Medical Center followed by a PGY2 Ambulatory Care Specialty Residency at the University of Georgia College of Pharmacy in conjunction with the Charlie Norwood VA Medical Center.
Relevant Financial Relationship Disclosures
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company.
More in this series
Finding Undiagnosed Atrial Fibrillation: Why, What, Who and How
The Time is Now: Equity in the Prescribing of DOACs for NVAF
Finding Hidden Stroke Risk: Screening for Atrial Fibrillation
Hidden in Plain Sight: Does My Patient Have Nonvalvular Atrial Fibrillation?
Shining a Light on Undiagnosed Nonvalvular Atrial Fibrillation: A Case-based Approach to Care
Provided by ASHP
Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance